Total Payments
$2,621
2023 Payments
$42.00
Companies
6
Transactions
18
Medicare Patients
708
Medicare Billing
$96,729
Payment Breakdown by Category
Consulting$2,000 (76.3%)
Food & Beverage$489.26 (18.7%)
Travel$89.56 (3.4%)
Education$42.00 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,000 | 2 | 76.3% |
| Food and Beverage | $489.26 | 13 | 18.7% |
| Travel and Lodging | $89.56 | 1 | 3.4% |
| Education | $42.00 | 2 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $2,202 | 4 | $0 (2020) |
| Genentech USA, Inc. | $196.89 | 9 | $0 (2021) |
| Amgen Inc. | $115.15 | 1 | $0 (2017) |
| Mirati Therapeutics, Inc. | $42.00 | 2 | $0 (2023) |
| TESARO, Inc. | $35.43 | 1 | $0 (2019) |
| Foundation Medicine, Inc. | $29.11 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $42.00 | 2 | Mirati Therapeutics, Inc. ($42.00) |
| 2021 | $18.89 | 1 | Genentech USA, Inc. ($18.89) |
| 2020 | $929.11 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($900.00) |
| 2019 | $123.56 | 7 | Genentech USA, Inc. ($88.13) |
| 2018 | $18.18 | 1 | Genentech USA, Inc. ($18.18) |
| 2017 | $1,489 | 5 | Bayer HealthCare Pharmaceuticals Inc. ($1,302) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/21/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2021 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: BioOncology | ||||||
| 04/22/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 01/24/2020 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $29.11 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2019 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: BioOncology | ||||||
| 05/11/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: BioOncology | ||||||
| 03/01/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: BioOncology | ||||||
| 02/22/2019 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: BioOncology | ||||||
| 02/08/2019 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: BioOncology | ||||||
| 02/01/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $35.43 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: BioOncology | ||||||
| 11/07/2018 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: BioOncology | ||||||
| 11/02/2017 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $115.15 | General |
| Category: Oncology | ||||||
| 10/25/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $71.69 | General |
| Category: BioOncology/Immunology | ||||||
| 06/16/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 06/16/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $89.56 | General |
| Category: Oncology | ||||||
| 05/10/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $112.68 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 170 | 271 | $48,879 | $23,687 |
| 2022 | 4 | 129 | 176 | $29,551 | $14,244 |
| 2021 | 6 | 194 | 316 | $61,763 | $31,045 |
| 2020 | 7 | 215 | 354 | $59,332 | $27,753 |
Total Patients
708
Total Services
1,117
Medicare Billing
$96,729
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 79 | 157 | $19,773 | $11,524 | 58.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 37 | 46 | $8,559 | $4,877 | 57.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 29 | 29 | $7,780 | $4,129 | 53.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 26 | $5,438 | $1,621 | 29.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $7,329 | $1,536 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 108 | $13,701 | $8,208 | 59.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $8,915 | $3,224 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 12 | $2,062 | $1,363 | 66.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 22 | $3,853 | $768.33 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $1,020 | $681.02 | 66.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 183 | $31,110 | $17,261 | 55.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 34 | 38 | $12,502 | $5,541 | 44.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 31 | $7,316 | $3,681 | 50.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $5,733 | $2,267 | 39.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 25 | $3,050 | $1,423 | 46.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 18 | $2,052 | $872.36 | 42.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 88 | 202 | $34,340 | $15,996 | 46.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 19 | $6,251 | $3,110 | 49.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 52 | $5,928 | $2,666 | 45.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $4,914 | $2,216 | 45.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 19 | 19 | $4,351 | $2,059 | 47.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 24 | $2,928 | $1,401 | 47.9% |
| 99406 | Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes | Office | 2020 | 15 | 20 | $620.00 | $304.38 | 49.1% |
About Dr. Borys Hrinczenko, MD
Dr. Borys Hrinczenko, MD is a Hematology healthcare provider based in Lansing, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376645085.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Borys Hrinczenko, MD has received a total of $2,621 in payments from pharmaceutical and medical device companies, with $42.00 received in 2023. These payments were reported across 18 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($2,000).
As a Medicare-enrolled provider, Hrinczenko has provided services to 708 Medicare beneficiaries, totaling 1,117 services with total Medicare billing of $96,729. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Lansing, MI
- Active Since 09/02/2006
- Last Updated 07/24/2024
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1376645085
Products in Payments
- Stivarga (Drug) $2,202
- Neulasta (Biological) $115.15
- Rituxan (Biological) $71.69
- Alecensa (Biological) $70.62
- KRAZATI (Drug) $42.00
- TECENTRIQ (Biological) $41.23
- ZEJULA (Drug) $35.43
- FOUNDATIONONE (Device) $29.11
- GAZYVA (Biological) $13.35
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Lansing
Craig Cole, Md, MD
Hematology — Payments: $93,447
Hematology $93,447
Dr. Elizabeth Layhe, D.o, D.O
Hematology — Payments: $507.34
Hematology $507.34
Dr. Rashi Gupta, M.d., M.p.h, M.D., M.P.H
Hematology — Payments: $123.86
Hematology $123.86
Ms. Lynette Oden, Technologist, TECHNOLOGIST
Hematology
Hematology